Schizophrenic Patients Taking Part in Integrated Care Program

AstraZeneca20 enrolled

Overview

Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia Schizoaffective Disorder Schizophreni-form Disorder Delusional Disorder Psychotic Disorder Not Otherwise Specified

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients suffering from schizophrenia, schizoaffective disorder, schizophreni-form disorder, delusional disorder or psychotic disorder not otherwise specified * Age 18 - 65 years * Current stable treatment with Seroquel according to SmPC since at least 2 months * Given consent to take part in an integrated care program prior to study startWritten informed consent to take part in this NIS Exclusion Criteria: * Presence of any contraindication as described in the SmPC * Cancellation of participation in the integrated care program

Locations (14)

Research Site

Ahrweiler, Germany

Research Site

Berlin, Germany

Research Site

Bonn, Germany

Research Site

Outcomes

Primary Outcomes

Subjective Well-Being measured via SWN patient questionnaire

Time frame: 6 month period of observation,4 assessments

Secondary Outcomes

Quality of Life and patient's satisfaction measured by Q-LES-Q-18 and CSQ-8

Time frame: 6 month period of observation, 1 assessment at end of NIS

Symptomatic and functional outcome measured by CGI-S, PANSS-8, GAF, EQ-5D and VOI

Time frame: 6 month period of observation, 4 assesments

Compliance and health economic aspects measured by MARS, days of hospitalization, productivity loss

Time frame: 6 month period of observation, 4 assesments

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.